GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations
For media and investors only
Issued: London, UK
Highlights
Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines
Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding...
Zur Pressemeldung auf www.gsk.com